A rapid High Performance Liquid Chromatography (HPLC) method for assay of Brivaracetam in Brivaracetam
Tablets (10mg and 100mg) has been developed and validated by using In-house methodology. Inertsil ODS 3V, 150mm x
4.6mm, 5µ HPLC column was used with variable wavelength detector (VWD) and photo diode array detector (PDA).
Chromatographic elution was carried out using a mixture of 0.1%v/v Trifluoroacetic acid solution and acetonitrile (60:40 v/v).
The wavelength used for detection was 210nm. The method was found to be precise, linear (with r2 = 0.99981), accurate,
specific, robust, rugged, stability indicating and suitable for its intended use. Brivaracetam was found to be degraded in greater
extent under basic condition. This method was found to be suitable for identification purpose.

The study was undertaken with an aim to formulate budesonide controlled release capsules. The drug budesonide is corticosteroid and used for the treatment of Crohn’s disease. Before going to develop the formulation, a detail product literature review was carried out to know about the innovator’s product and the patent status of the drug. Preformulation study involving drug -excipients compatibility was done initially and results indicated the compatibility with all the tested excipients. The study was carried out by solution/suspension matrix layering method. In this method first drug and polymer solutions were mixed, coating was done on the sugar spheres; further enteric coating was done on polymer matrix coated pellets. Different trials were conducted with various percentages of polymer in first stage and second stage (during enteric coating), and the formulation was finally optimized based on the drug release profile. Pellets were evaluated by in vitro dissolution. These studies revealed that the F6 pellets were found to be release the drug almost comparable to that of innovator’s product. Further, the F6 formulation was subjected to release studies at different pH conditions and found to have similar release profile as that of innovator. The in vitro dissolution tests were performed and f2 values were calculated for all trials. Dissolution profile of formulation F6 matched with that of the innovator’s product and f2 value was satisfactory. Stability studies were also performed; both accelerated and long term stability studies were conducted for two months. During this study, the formulation F6 was found to be stable and no differences in the assay and release characteristics were noticed

Gemfibrozil is used along with a proper diet to help lower fats (triglycerides) and raise "good" cholesterol (HDL) in the blood. Floating gastro retentive tablets containing Gemfibrozil were prepared using direct compression method. Total nine formulations were prepared using varying amount of HPMC-K4 and HPMC-K15. The prepared Tablets were further evaluated for Hardness, Friability, floating behavior, and uniformity of drug content, and In-vitro Release Studies. Percentage assay of different formulation was determined by weighing the Microspheres after drying. The percentage yield of different formulation was in range of 95.58±0.54-98.96±0.65%. The maximum percentage buoyancy and floating lag time was found to be formulation F7 in gastro retentive tablets. The optimized formulation of batches subjected to further studies. When the regression coefficient values of were compared, it was observed that ‘r’ values of First order was maximum i.e. 0.990 hence indicating drug release from formulations was found to follow First order Hixson-Crowell release kinetics. The in vitro dissolution studies showed that Gemfibrozil tablets formulation F7 showed better sustained effect over a period of 12 hours than floating formulations.

The present study was an attempt to formulate a gastro-retentive floating drug delivery system of Ambroxol Hydrochloride, in order to improve its gastric residence time and bioavailability. Floating lag time, and hardness of the tablets of Ambroxol Hydrochloride, by applying the optimization technique. The data from the release profile were fitted to various mathematical models, and fitting to the Korsmeyer and Peppas equation revealed that the release mechanism from the dosage form followed the non-fickian transport

The aim this work was to formulate and evaluate multiunit floating microspheres containing Losartan Potassium. The floating microspheres were prepared by Ionotropic Gelation method with the polymer combination of hyroxipropyl methyl cellulose and ethyl cellulose. Losartan potassium is an orally active non-peptide angiotensin-II receptor antagonist and it is readily absorbed from the stomach and upper part of small intestine. The prepared microspheres were evaluated for particle size, encapsulation efficiency, swelling index, buoyancy and drug release. The drug encapsulation efficiency varied from between 53.69 to 75.6 depends upon the drug polymer ratio. The mean particle size of selected batch was 973.5 um. The study on in vitro release of all formulation in 0.1 N HCl, the maximum % CDR observed in F5 at the period of 10 hrs. F5 followed zero order and shows controlled release of drug thus reduce frequency of dosing, minimizing of side effects, improve bioavailability and increase the effectiveness of the drug.

Ornidazole is a synthetic nitroimidazole used for treatment of infections caused by both anaerobic bacteria and protozoa. It has short half-life, makes the sustained release (SR) forms extremely advantageous. Sustained release tablets results in increased bioavailability. The purpose of the present study was to develop a sustain release matrix drug delivery system (SR) containing Ornidazole as a model drug by using various proportions of polymers such as HPMC E15, HPMC K15. The sustained release formulations of Ornidazole were prepared by direct compression method. Optimization of formulation was done by studying effect of drug to polymer ratio on drug release. FT-IR studies indicated absence of any interaction between Ornidazole, polymers (HPMC E15 and HPMC K15) and excipients. Ten formulations were prepared and Formulation F8 possesses good drug release property. The tablets were also evaluated for its hardness, friability and other In-vitro evaluation tests. All parameters complied with IP limits. Drug release was diffusion controlled and followed Zero order kinetics. Non-Fickian diffusion was the drug release mechanism for all the tablets formulated.

Out of all the cancers colon cancer is one of the most common cancers in the world. Every year 1.2 million patients are
diagnosed for colon cancer. The rate of colon cancer incidence was low in India but is presently increasing; out of 3.5 million
cancer cases, 35,000 suffer from colon cancer. Phytochemically the plant has been investigated for cardenolides, alkaloids,
triterpenes and saponins and it is found to contain a variety of triterpenes and steroidal compounds and also to find out, a newer
synthetic drug, for its anti-colon cancer potential and its toxic profile. Two formulations were prepared using herbs and they
were compared for their anti-cancer activity. Two kinds of polyherbal formulations were prepared using different extracts and
they were tested for anti-cancer activity invitro. Formulations with potent drugs like ashwagandha and colchicum showed a
potent activity than other formulation. Before the clinical usage of extract, thorough toxicological profile has to be determined
on the crude extracts as well as on isolated compounds to confirm the safety of the drug.

Eugenol in therapeutic doses has not been implicated in causing serum enzyme elevations or clinically apparent liver
injury, but ingestions of high doses, as with an overdose, can cause severe liver injury. Eugenol is used as a component of
several dental materials. They are reported to be widely used in dentistry as temporary filing materials, cavity liners for pulp
protection, capping materials, temporary cementation of fixed protheses, impression materials and major ingredients of
endodontic sealers. In addition, eugenol has been used in dentistry for disinfecting root canals. In vitro, eugenol has been shown
to have antibacterial, antifungal, antioxidant and antineoplastic activity. This UV-spectrophotometric technique is quite simple,
accurate, precise, reproducible, and sensitive. The UV method has been developed for quantification of Eugenol in tablet
formulation. The validation procedure confirms that this is an appropriate method for their quantification in the formulation. It
is also used in routine quality control of the formulations containing this entire compound